Back

Baseline surveillance profile of doripenem against key Gram-negative pathogens encountered in Europe

Abstract number: 1733_1160

Aranza M.K., Draghi D.C., Jones M.E., Thornsberry C., Sahm D.F.

Background: DOR, is an investigational parenteral broad-spectrum 1-b-methyl carbapenem that is refractory to hydrolysis by most Gram-negative b-lactamases. It is under clinical development for complicated urinary tract infections, complicated intra-abdominal infections, and hospital acquired pneumonia (including ventilator-associated pneumonia). As a key component of the development programme, this surveillance initiative was done to establish baseline data on DOR activity against recent Gram-negative pathogens relative to other key b-lactam agents.

Methods: During 2005–2006, Citrobacter spp. (CP; n = 387), E. cloacae (EA; n = 406), E. coli (EC;n = 1213), K. pneumoniae (KP;n = 854), P. mirabilis (PM;n = 443), S. marcescens (SM; n = 291), P. aeruginosa (PA;n = 621), and Acinetobacter spp. (AC;n = 278) collected from 31 institutions in 12 European countries were centrally tested by broth microdilution (CLSI; M7-A6). Testing included DOR, imipenem (IMP), ceftazidime (CAZ), cefepime (FEP), piperacillin-tazobactam (PTZ) and other relevant agents.

Results: See the table.

OrgaMICb (mg/L)
DORIMPCAZFEPPTZ
RangeM90RangeM90RangeM90RangeM90RangeM90 
CP<=0.015–80.060.06–322<=0.03–>32>32<=0.015–>321<=0.25–>12864
EA<=0.015–10.12<=0.015–42<=0.03–>32>32<=0.015–>328<=0.25–>128>128
EC<=0.015–0.50.03<=0.015–40.5<=0.03–>322<=0.015–>321<=0.25–>12864
KP<=0.015–80.060.06–161<=0.03–>32>32<=0.015–32>320.5–128>128
PM<=0.015–20.250.06–324<=0.03–>320.12<=0.015–>320.12<=0.25–1282
SM<=0.015–10.250.25–44<=0.03–>322<=0.015–>3211–>12864
PA<=0.015–>3240.25–>32320.06–>32>32<=0.015–>32160.5–>128>128
AC<=0.015–>3232<=0.015–>32>320.06–>32>320.06–>32>32<=0.25–>128>128
aOrg, Organism; bM90: MIC90.

Conclusions: Based on MIC90s, for every organism group surveyed, including PA, DOR's in vitro activity was comparable or more active than a carbapenem (IMP), the cephalosporins (CAZ, FEP), and a b-lactam (PTZ). These findings establish an important baseline for continued tracking of DOR activity as clinical development continues.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top